癌症中的免疫反应反映了一系列精心调控的事件；然而，当前的肿瘤免疫疗法通常针对增强抗肿瘤免疫力的一个关键方面。在本研究中，我们开发了一种基于纳米平台（Fe3O4@IR820@CpG）的免疫治疗策略，该策略针对癌症免疫周期中的多个关键步骤：1）促进肿瘤衍生蛋白（TDP）的释放，包括肿瘤-相关抗原和促免疫刺激因子），除了直接杀伤作用外，还通过光热疗法（PTT）和光动力疗法（PDT）； 2) 捕获释放的 TDP 并将其与 CpG（Toll 样受体 9 [TLR-9] 激动剂）一起递送至抗原呈递细胞 (APC)，以促进抗原呈递和 T 细胞激活； 3）与抗程序性死亡配体1抗体（α-PD-L1）结合，增强T细胞的杀伤肿瘤能力，共同提升了我们对结直肠癌、肝癌和乳腺癌的卓越抗肿瘤效果。 Fe3 O4 @IR820@CpG 与 α-PD-L1 的广谱抗肿瘤活性表明，优化地控制抗癌免疫不是单独的，而是作为一个整体提供有前途的临床策略。本文受版权保护。保留所有权利。本文受版权保护。版权所有。

The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti-tumor immunity. In the present study, we developed a nanoplatform (Fe3 O4 @IR820@CpG)-based immunotherapy strategy that targets the multiple key steps in cancer-immunity cycle: 1) promotes the release of tumor-derived proteins (TDPs), including tumor-associated antigens and pro-immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll-like receptor 9 [TLR-9] agonist) to antigen presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor-killing ability of T cells by combining with anti-programmed death ligand 1 antibody (α-PD-L1), which collectively advances our outstanding of the anti-tumor effects on colorectal, liver and breast cancers. The broad-spectrum anti-tumor activity of Fe3 O4 @IR820@CpG with α-PD-L1 demonstrated that optimally manipulating anti-cancer immunity not singly but as a group provides promising clinical strategies. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.